What Animal Models Have Taught Us About the Safety and Efficacy of Bisphosphonates in Chronic Kidney Disease

Matthew Allen, Mohammad W. Aref

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose of Review: Bisphosphonates (BPs) have long been the gold-standard anti-remodeling treatment for numerous metabolic bone diseases. Since these drugs are excreted unmetabolized through the kidney, they are not recommended for individuals with compromised kidney function due to concerns of kidney and bone toxicity. The goal of this paper is to summarize the preclinical BP work in models of kidney disease with particular focus on the bone, kidney, and vasculature. Recent Findings: Summative data exists showing positive effects on bone and vascular calcifications with minimal evidence for bone or kidney toxicity in animal models. Summary: Preclinical data suggest it may be worthwhile to take a step back and reconsider the use of bisphosphonates to lessen skeletal/vascular complications associated with compromised kidney function.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalCurrent Osteoporosis Reports
DOIs
StateAccepted/In press - Apr 21 2017

Fingerprint

Diphosphonates
Chronic Renal Insufficiency
Animal Models
Kidney
Safety
Bone and Bones
Vascular Calcification
Metabolic Bone Diseases
Kidney Diseases
Gold
Blood Vessels
Pharmaceutical Preparations

Keywords

  • Anti-resorptive agents
  • Bone mechanics
  • Bone remodeling
  • CKD
  • Renal osteodystrophy
  • Vascular calcification

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

@article{fb32e769268e49fd9c521a0cc11c1730,
title = "What Animal Models Have Taught Us About the Safety and Efficacy of Bisphosphonates in Chronic Kidney Disease",
abstract = "Purpose of Review: Bisphosphonates (BPs) have long been the gold-standard anti-remodeling treatment for numerous metabolic bone diseases. Since these drugs are excreted unmetabolized through the kidney, they are not recommended for individuals with compromised kidney function due to concerns of kidney and bone toxicity. The goal of this paper is to summarize the preclinical BP work in models of kidney disease with particular focus on the bone, kidney, and vasculature. Recent Findings: Summative data exists showing positive effects on bone and vascular calcifications with minimal evidence for bone or kidney toxicity in animal models. Summary: Preclinical data suggest it may be worthwhile to take a step back and reconsider the use of bisphosphonates to lessen skeletal/vascular complications associated with compromised kidney function.",
keywords = "Anti-resorptive agents, Bone mechanics, Bone remodeling, CKD, Renal osteodystrophy, Vascular calcification",
author = "Matthew Allen and Aref, {Mohammad W.}",
year = "2017",
month = "4",
day = "21",
doi = "10.1007/s11914-017-0361-4",
language = "English (US)",
pages = "1--7",
journal = "Current Alzheimer Research",
issn = "1546-9530",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - What Animal Models Have Taught Us About the Safety and Efficacy of Bisphosphonates in Chronic Kidney Disease

AU - Allen, Matthew

AU - Aref, Mohammad W.

PY - 2017/4/21

Y1 - 2017/4/21

N2 - Purpose of Review: Bisphosphonates (BPs) have long been the gold-standard anti-remodeling treatment for numerous metabolic bone diseases. Since these drugs are excreted unmetabolized through the kidney, they are not recommended for individuals with compromised kidney function due to concerns of kidney and bone toxicity. The goal of this paper is to summarize the preclinical BP work in models of kidney disease with particular focus on the bone, kidney, and vasculature. Recent Findings: Summative data exists showing positive effects on bone and vascular calcifications with minimal evidence for bone or kidney toxicity in animal models. Summary: Preclinical data suggest it may be worthwhile to take a step back and reconsider the use of bisphosphonates to lessen skeletal/vascular complications associated with compromised kidney function.

AB - Purpose of Review: Bisphosphonates (BPs) have long been the gold-standard anti-remodeling treatment for numerous metabolic bone diseases. Since these drugs are excreted unmetabolized through the kidney, they are not recommended for individuals with compromised kidney function due to concerns of kidney and bone toxicity. The goal of this paper is to summarize the preclinical BP work in models of kidney disease with particular focus on the bone, kidney, and vasculature. Recent Findings: Summative data exists showing positive effects on bone and vascular calcifications with minimal evidence for bone or kidney toxicity in animal models. Summary: Preclinical data suggest it may be worthwhile to take a step back and reconsider the use of bisphosphonates to lessen skeletal/vascular complications associated with compromised kidney function.

KW - Anti-resorptive agents

KW - Bone mechanics

KW - Bone remodeling

KW - CKD

KW - Renal osteodystrophy

KW - Vascular calcification

UR - http://www.scopus.com/inward/record.url?scp=85018812226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018812226&partnerID=8YFLogxK

U2 - 10.1007/s11914-017-0361-4

DO - 10.1007/s11914-017-0361-4

M3 - Article

C2 - 28432595

AN - SCOPUS:85018812226

SP - 1

EP - 7

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1546-9530

ER -